Latest News From "The Pink Sheet" DAILY - Ipilimumab, Crizotinib Study Results Unveiled At ASCO

Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight

Phase III results highlight need for management of immune-related side effects with vigilant monitoring and early steroid treatment.   read more

 

Crizotinib Holds Promise For Lung Cancer, And For Pfizer Oncology

The targeted ALK inhibitor is on an accelerated track, with initial Phase I unveiled at ASCO annual meeting and a registration program already under way.   read more

 

FDA Finalizing Opioid REMS Proposal, Sets Joint Advisory Committee Meeting For July

FDA wants to gather feedback from advisors and from the public on the classwide REMS for opioid analgesics, and judging from the stakeholder meetings the agency has held so far, it will get an earful.   read more

 

Sanofi-Aventis To Co-Develop HDM2 Inhibitors For Cancer With Ascenta

Ascenta hopes to develop targeted cancer drugs that will be less toxic than standard chemotherapy and less expensive than biologics.   read more

 

Big Brand Fights Come To India As Januvia, Galvus And Onglyza Vie For Market Share

Marketing of patented and branded drugs is a relatively new concept in India but going by the initial strategies put into play by multinational companies it has all the ingredients of blowing up into an all-out war in the race to capture the mind recall of doctors prescribing anti-diabetics.   read more

 

Financings Of The Fortnight: Tough To Diagnose Meaning Of Genmark's IPO

The small diagnostic firm's reverse merger followed by a smallish IPO might be a harbinger of financings to come. Or not.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here